REVIEW ARTICLE
Therapeutic Effects of the major alkaloid constituents of Evodia rutaecarpa in Alzheimer's disease
Qingyu Cao,
Peiliang Dong,
Hua Han,
Qingyu Cao
Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Search for more papers by this authorCorresponding Author
Peiliang Dong
Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Correspondence: Peiliang Dong, Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150000, China. Email: [email protected]
Hua Han, College of Medicine, Heilongjiang University of Chinese Medicine. Harbin 150000, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Hua Han
College of Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Correspondence: Peiliang Dong, Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150000, China. Email: [email protected]
Hua Han, College of Medicine, Heilongjiang University of Chinese Medicine. Harbin 150000, China. Email: [email protected]
Search for more papers by this authorQingyu Cao,
Peiliang Dong,
Hua Han,
Qingyu Cao
Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Search for more papers by this authorCorresponding Author
Peiliang Dong
Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Correspondence: Peiliang Dong, Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150000, China. Email: [email protected]
Hua Han, College of Medicine, Heilongjiang University of Chinese Medicine. Harbin 150000, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Hua Han
College of Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
Correspondence: Peiliang Dong, Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150000, China. Email: [email protected]
Hua Han, College of Medicine, Heilongjiang University of Chinese Medicine. Harbin 150000, China. Email: [email protected]
Search for more papers by this authorFirst published: 03 January 2024
Abstract
Since the report of Alzheimer's disease (AD) in 1907, it has garnered widespread attention due to its intricate pathogenic mechanisms, significant impact on patients' lives, and the substantial burden it places on society. Presently, effective treatments for AD remain elusive. Recent pharmacological studies on the traditional East Asian herb, Evodia rutaecarpa, have revealed that the bioactive alkaloid components within it can ameliorate AD-related cognitive impairments and neurological damage through various pathways, including anti-inflammatory, antioxidant, and anti-acetylcholinesterase activities. Consequently, this article provides an overview of the pharmacological effects and research status of the four main alkaloid components found in Evodia concerning AD. We hope this article will serve as a valuable reference for experimental and clinical research on the use of Evodia in AD prevention and treatment.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
References
- 1Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep 2015; 67: 195–203.
- 2Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature 2010; 464: 529–535.
- 3Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 2021; 17: 157–172.
- 4Bai R, Guo J, Ye XY, Xie Y, Xie T. Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease. Ageing Res Rev 2022; 77: 101619.
- 5Akash MSH, Akbar M, Rehman K et al. Biochemical profiling of berberine-enriched extract in aluminum chloride induced oxidative damage and neuroinflammation. Environ Sci Pollut Res Int 2023; 30: 85263–85275.
- 6Zhang Z, Yang X, Song YQ, Tu J. Autophagy in Alzheimer's disease pathogenesis: therapeutic potential and future perspectives. Ageing Res Rev 2021; 72: 101464.
- 7De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell 2016; 164: 603–615.
- 8Zhang L et al. Elucidation of pharmacological mechanism underlying the anti-Alzheimer's disease effects of Evodia rutaecarpa and discovery of novel Lead molecules: An in silico study. Molecules 2023; 28: 5846.
- 9Li M, Wang C. Traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the fruit of Tetradium ruticarpum: a review. J Ethnopharmacol 2020; 263: 113231.
- 10Yang S et al. Analysis of E. Rutaecarpa alkaloids constituents in vitro and in vivo by UPLC-Q-TOF-MS combined with diagnostic fragment. J Anal Methods Chem 2016; 2016: 4218967.
- 11Zhang YN, Yang YF, Yang XW. Blood-brain barrier permeability and neuroprotective effects of three main alkaloids from the fruits of Euodia rutaecarpa with MDCK-pHaMDR cell monolayer and PC12 cell line. Biomed Pharmacother 2018; 98: 82–87.
- 12Wang X, Wang R, Xing D et al. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 2005; 77: 3058–3067.
- 13Huang G, Kling B, Darras FH, Heilmann J, Decker M. Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. Eur J Med Chem 2014; 81: 15–21.
- 14Pang S et al. Discovery of an evodiamine derivative for PI3K/AKT/GSK3beta pathway activation and AD pathology improvement in mouse models. Front Mol Neurosci 2022; 15: 1025066.
- 15Mrvova N et al. Modulation of BV-2 microglia functions by novel quercetin pivaloyl ester. Neurochem Int 2015; 90: 246–254.
- 16Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382–397.
- 17Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21–28.
- 18Byeon SE et al. The role of Src kinase in macrophage-mediated inflammatory responses. Mediators Inflamm 2012; 2012: 512926.
- 19Chiou WF, Sung YJ, Liao JF, Shum AYC, Chen CF. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 1997; 60: 708–711.
- 20Choi YH, Shin EM, Kim YS, Cai XF, Lee JJ, Kim HP. Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch Pharm Res 2006; 29: 293–297.
- 21Yuan SM, Gao K, Wang DM et al. Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(DeltaE9) transgenic mouse models of Alzheimer's disease. Acta Pharmacol Sin 2011; 32: 295–302.
- 22Fan X, Zhu JY, Sun Y et al. Evodiamine inhibits zymosan-induced inflammation in vitro and in vivo: inactivation of NF-kappaB by inhibiting IkappaBalpha phosphorylation. Inflammation 2017; 40: 1012–1027.
- 23Meng T, Fu S, He D et al. Evodiamine inhibits lipopolysaccharide (LPS)-induced inflammation in BV-2 cells via regulating AKT/Nrf2-HO-1/NF-kappaB signaling Axis. Cell Mol Neurobiol 2021; 41: 115–127.
- 24Ko HC, Wang YH, Liou KT et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 2007; 555: 211–217.
- 25Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
- 26Wang D, Wang C, Liu L, Li S. Protective effects of evodiamine in experimental paradigm of Alzheimer's disease. Cogn Neurodyn 2018; 12: 303–313.
- 27Zhang Y, Wang J, Wang C et al. Pharmacological basis for the use of evodiamine in Alzheimer's disease: antioxidation and Antiapoptosis. Int J Mol Sci 2018; 19: 1527.
- 28Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306: 990–995.
- 29Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006; 66: 9349–9351.
- 30Chou CH, Yang CR. Neuroprotective studies of evodiamine in an okadaic acid-induced neurotoxicity. Int J Mol Sci 2021; 22: 5347.
- 31Jiang ML, Zhang ZX, Li YZ, Wang XH, Yan W, Gong GQ. Antidepressant-like effect of evodiamine on chronic unpredictable mild stress rats. Neurosci Lett 2015; 588: 154–158.
- 32Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. Neuromolecular Med 2008; 10: 259–274.
- 33Liu YN, Pan SL, Liao CH et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock 2009; 32: 263–269.
- 34Zhao T, Zhang X, Zhao Y et al. Pretreatment by evodiamine is neuroprotective in cerebral ischemia: up-regulated pAkt, pGSK3beta, down-regulated NF-kappaB expression, and ameliorated BBB permeability. Neurochem Res 2014; 39: 1612–1620.
- 35Wang T, Kusudo T, Takeuchi T et al. Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice. PLoS One 2013; 8: e83264.
- 36Li Z, Wang B, Hou JQ et al. 2-(2-indolyl-)-4(3H)-quinazolines derivates as new inhibitors of AChE: design, synthesis, biological evaluation and molecular modelling. J Enzyme Inhib Med Chem 2013; 28: 583–592.
- 37Huang XF, Dong YH, Wang JH, Ke HM, Song GQ, Xu DF. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2020; 30: 127097.
- 38Ahmad SS, Sinha M, Ahmad K, Khalid M, Choi I. Study of caspase 8 inhibition for the Management of Alzheimer's disease: a molecular docking and dynamics simulation. Molecules 2020; 25: 2071.
- 39Dzamko N, Gysbers A, Perera G et al. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol 2017; 133: 303–319.
- 40Jayakumar T, Yang CM, Yen TL et al. Anti-inflammatory mechanism of An alkaloid Rutaecarpine in LTA-stimulated RAW 264.7 cells: pivotal role on NF-kappaB and ERK/p38 signaling molecules. Int J Mol Sci 2022; 23: 5889.
- 41Jayakumar T, Lin KC, Chang CC et al. Targeting MAPK/NF-kappaB pathways in anti-inflammatory potential of Rutaecarpine: impact on Src/FAK-mediated macrophage migration. Int J Mol Sci 2021; 23: 92.
- 42Woo HG et al. Rutaecarpine, a quinazolinocarboline alkaloid, inhibits prostaglandin production in RAW264.7 macrophages. Planta Med 2001; 67: 505–509.
- 43Son JK, Chang HW, Jahng Y. Progress in studies on Rutaecarpine. II.—synthesis and structure-biological activity relationships. Molecules 2015; 20: 10800–10821.
- 44Wang B, Mai YC, Li Y et al. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem 2010; 45: 1415–1423.
- 45Qin XP, Zeng SY, Li D et al. Calcitonin gene-related peptide-mediated depressor effect and inhibiting vascular hypertrophy of rutaecarpine in renovascular hypertensive rats. J Cardiovasc Pharmacol 2007; 50: 654–659.
- 46Nie XQ, Chen HH, Zhang JY et al. Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways. Acta Pharmacol Sin 2016; 37: 483–496.
- 47Surbala L, Singh CB, Devi RV, Singh OJ. Rutaecarpine exhibits anti-diabetic potential in high fat diet-multiple low dose streptozotocin induced type 2 diabetic mice and in vitro by modulating hepatic glucose homeostasis. J Pharmacol Sci 2020; 143: 307–314.
- 48Yan C, Zhang J, Wang S, Xue G, Hou Y. Neuroprotective effects of rutaecarpine on cerebral ischemia reperfusion injury. Neural Regen Res 2013; 8: 2030–2038.
- 49Han M, Hu L, Chen Y. Rutaecarpine may improve neuronal injury, inhibits apoptosis, inflammation and oxidative stress by regulating the expression of ERK1/2 and Nrf2/HO-1 pathway in rats with cerebral ischemia-reperfusion injury. Drug des Devel Ther 2019; 13: 2923–2931.
- 50Xu M, Li L, Liu H, Lu W, Ling X, Gong M. Rutaecarpine attenuates oxidative stress-induced traumatic brain injury and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Front Pharmacol 2022; 13: 807125.
- 51Han XH, Hong SS, Lee D et al. Quinolone alkaloids from evodiae fructus and their inhibitory effects on monoamine oxidase. Arch Pharm Res 2007; 30: 397–401.
- 52Fu S, Liao L, Yang Y et al. The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: a review. Front Pharmacol 2022; 13: 1040154.
- 53Park CH, Lee YJ, Lee SH et al. Dehydroevodiamine.HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance. J Neurochem 2000; 74: 244–253.
- 54Park EJ, Suh YH, Kim JY, Choi S, Lee CJ. Long-lasting facilitation by dehydroevodiamine. HClof synaptic responses evoked in the CA1 region of rat hippocampal slices. Neuroreport 2003; 14: 399–403.
- 55Kim HJ, Shin KY, Chang KA et al. Dehydroevodiamine.HCl improves stress-induced memory impairments and depression like behavior in rats. Korean. J Physiol Pharmacol 2014; 18: 55–59.
- 56Shin KY, Kim KY, Suh YH. Dehydroevodiamine.HCl enhances cognitive function in memory-impaired rat models. Korean. J Physiol Pharmacol 2017; 21: 55–64.
- 57Park CH et al. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med 1996; 62: 405–409.
- 58Ahmad SS, Khan MB, Ahmad K et al. Biocomputational screening of natural compounds against acetylcholinesterase. Molecules 2021; 26: 2641.
- 59Collingridge GL, Lester RA. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989; 41: 143–210.
- 60Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379–387.
- 61Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987; 7: 357–368.
- 62Lim DK, Lee YB, Kim HS. Effects of dehydroevodiamine exposure on glutamate release and uptake in the cultured cerebellar cells. Neurochem Res 2004; 29: 407–411.
- 63Noh EJ, Ahn KS, Shin EM, Jung SH, Kim YS. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci 2006; 79: 695–701.
- 64Shin KY, Noh S-J, Park CH et al. Dehydroevodiamine•HCl protects against memory impairment and cerebral amyloid-β production in Tg2576 mice by acting as a β-secretase inhibitor. CNS Neurol Disord Drug Targets 2016; 15: 935–944.
- 65Fang J, Liu R, Tian Q et al. Dehydroevodiamine attenuates calyculin A-induced tau hyperphosphorylation in rat brain slices. Acta Pharmacol Sin 2007; 28: 1717–1723.
- 66Peng JH, Zhang CE, Wei W, Hong XP, Pan XP, Wang JZ. Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats. Neuropharmacology 2007; 52: 1521–1527.
- 67Kang S, Ha S, Park H et al. Effects of a Dehydroevodiamine-derivative on synaptic destabilization and memory impairment in the 5xFAD, Alzheimer's disease mouse model. Front Behav Neurosci 2018; 12: 273.
- 68Fang Z, Tang Y, Ying J, Tang C, Wang Q. Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa. Chin Med 2020; 15: 82.
- 69Durairajan SS et al. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol Aging 2012; 33: 2903–2919.
- 70Huang M, Jiang X, Liang Y, Liu Q, Chen S, Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of beta-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease. Exp Gerontol 2017; 91: 25–33.
- 71Cai Z, Wang C, He W, Chen Y. Berberine alleviates amyloid-Beta pathology in the brain of APP/PS1 transgenic mice via inhibiting beta/gamma-secretases activity and enhancing alpha-secretases. Curr Alzheimer Res 2018; 15: 1045–1052.
- 72Kumar A, Ekavali, Mishra J, Chopra K, Dhull DK. Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction. Psychopharmacology (Berl) 2016; 233: 137–152.
- 73Sadraie S, Kiasalari Z, Razavian M et al. Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: insights into underlying molecular mechanisms. Metab Brain Dis 2019; 34: 245–255.
- 74Hussien HM, Abd-Elmegied A, Ghareeb DA, Hafez HS, Ahmed HEA, el-moneam NA. Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer's-like disease in rats. Food Chem Toxicol 2018; 111: 432–444.
- 75Ge Y, Song X, Liu J, Liu C, Xu C. The combined therapy of berberine treatment with lncRNA BACE1-AS depletion attenuates Abeta(25-35) induced neuronal injury through regulating the expression of miR-132-3p in neuronal cells. Neurochem Res 2020; 45: 741–751.
- 76Guo Q et al. SOCS1 mediates berberine-induced amelioration of microglial activated states in N9 microglia exposed to beta amyloid. Biomed Res Int 2021; 2021: 9311855.
- 77Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci 2021; 22: 6355.
- 78Vassar R, Bennett BD, Babu-Khan S et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741.
- 79Asai M, Iwata N, Yoshikawa A et al. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun 2007; 352: 498–502.
- 80Zhu F, Wu F, Ma Y et al. Decrease in the production of beta-amyloid by berberine inhibition of the expression of beta-secretase in HEK293 cells. BMC Neurosci 2011; 12: 125.
- 81Zhang H, Zhao C, Cao G et al. Berberine modulates amyloid-beta peptide generation by activating AMP-activated protein kinase. Neuropharmacology 2017; 125: 408–417.
- 82Xue Z, Guo Y, Zhang S et al. Beta-asarone attenuates amyloid beta-induced autophagy via Akt/mTOR pathway in PC12 cells. Eur J Pharmacol 2014; 741: 195–204.
- 83Nilsson P, Loganathan K, Sekiguchi M et al. Abeta secretion and plaque formation depend on autophagy. Cell Rep 2013; 5: 61–69.
- 84Cai ZY, Wang CL, Lu TT, Yang WM. Berberine alleviates amyloid-beta pathogenesis via activating LKB1/AMPK signaling in the brain of APP/PS1 transgenic mice. Curr Mol Med 2019; 19: 342–348.
- 85Wang YY, Yan Q, Huang ZT et al. Ameliorating ribosylation-induced amyloid-beta pathology by berberine via inhibiting mTOR/p70S6K signaling. J Alzheimers Dis 2021; 79: 833–844.
- 86Yu G, Li Y, Tian Q et al. Berberine attenuates calyculin A-induced cytotoxicity and tau hyperphosphorylation in HEK293 cells. J Alzheimers Dis 2011; 24: 525–535.
- 87Chen Y, Chen Y, Liang Y, Chen H, Ji X, Huang M. Berberine mitigates cognitive decline in an Alzheimer's disease mouse model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed Pharmacother 2020; 121: 109670.
- 88Jia L, Liu J, Song Z et al. Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways. J Pharm Pharmacol 2012; 64: 1510–1521.
- 89He W, Wang C, Chen Y, He Y, Cai Z. Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-kappaB signaling, oxidative stress and neuroinflammation. Pharmacol Rep 2017; 69: 1341–1348.
- 90Tonnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer's disease. J Alzheimers Dis 2017; 57: 1105–1121.
- 91Liu X, Zhou J, Abid MDN et al. Correction: berberine attenuates axonal transport impairment and axonopathy induced by Calyculin a in N2a cells. PloS One 2016; 11: e0152609.
- 92de Oliveira JS, Abdalla FH, Dornelles GL et al. Neuroprotective effects of berberine on recognition memory impairment, oxidative stress, and damage to the purinergic system in rats submitted to intracerebroventricular injection of streptozotocin. Psychopharmacology (Berl) 2019; 236: 641–655.
- 93Wen C, Huang C, Yang M et al. The secretion from bone marrow mesenchymal stem cells pretreated with berberine rescues neurons with oxidative damage through activation of the Keap1-Nrf2-HO-1 signaling pathway. Neurotox Res 2020; 38: 59–73.
- 94Zhang RL, Lei BX, Wu GY, Wang YY, Huang QH. Protective effects of berberine against beta-amyloid-induced neurotoxicity in HT22 cells via the Nrf2/HO-1 pathway. Bioorg Chem 2023; 133: 106210.
- 95Wang C, Zou Q, Pu Y, Cai Z, Tang Y. Berberine rescues D-ribose-induced Alzheimer's pathology via promoting mitophagy. Int J Mol Sci 2023; 24: 5896.
- 96Wong LR, Tan EA, Lim MEJ et al. Functional effects of berberine in modulating mitochondrial dysfunction and inflammatory response in the respective amyloidogenic cells and activated microglial cells – in vitro models simulating Alzheimer's disease pathology. Life Sci 2021; 282: 119824.
- 97Zhao C et al. Berberine alleviates amyloid beta-induced mitochondrial dysfunction and synaptic loss. Oxid Med Cell Longev 2019; 2019: 7593608.
- 98Li X, Chen J, Feng W et al. Berberine ameliorates iron levels and ferroptosis in the brain of 3 x Tg-AD mice. Phytomedicine 2023; 118: 154962.
- 99Liang Y, Huang M, Jiang X, Liu Q, Chang X, Guo Y. The neuroprotective effects of berberine against amyloid beta-protein-induced apoptosis in primary cultured hippocampal neurons via mitochondria-related caspase pathway. Neurosci Lett 2017; 655: 46–53.
- 100Chen M, Li L, Liu C, Song L. Berberine attenuates Abeta-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer's disease. Mol Cell Biochem 2020; 474: 285–294.
